(Q34773714)

4 August 2017

1 reference

title

Control of nausea and vomiting after chemotherapy: what is the evidence? (English)

1 reference

4 August 2017

1 reference

Bartlett N

1

1 reference

4 August 2017

Koczwara B

series ordinal

2

1 reference

4 August 2017

publication date

1 August 2002

1 reference

Internal Medicine Journal

4 August 2017

published in

1 reference

4 August 2017

volume

32

1 reference

4 August 2017

issue

8

1 reference

4 August 2017

page(s)

401-407

1 reference

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Impact of tumour burden on chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Instit

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Delayed emesis: a dilemma in antiemetic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Novel approaches to the treatment of nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Acupuncture: an evidence-based review of the clinical literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00259.X

10.1046/J.1445-5994.2002.00259.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference